STOCK TITAN
  1. Home
  2. News
  3. QTRX

Quanterix Corporation - QTRX STOCK NEWS

Welcome to our dedicated page for Quanterix Corporation news (Ticker: QTRX), a resource for investors and traders seeking the latest updates and insights on Quanterix Corporation stock.

Quanterix Corporation (NASDAQ: QTRX) is a pioneering life sciences company renowned for its groundbreaking ultra-sensitive diagnostic platform. This innovative technology measures individual proteins at concentrations that are up to 1000 times lower than the best immunoassays available today.

At the core of Quanterix's offerings is the Single Molecule Array (Simoa™) technology, which enables the detection and quantification of biomarkers that were previously difficult or impossible to measure. This advancement opens up new applications in various fields, including life sciences research, in-vitro diagnostics, companion diagnostics, and blood screening.

Founded by the esteemed scientist Dr. David Walt, who also co-founded Illumina, Quanterix benefits from a robust intellectual property portfolio initially developed at Tufts University. The company is venture capital-backed and has exclusive licensing rights to this broad IP portfolio.

Quanterix's product lineup is diverse and includes:

  • Simoa platform
  • Assay Kits
  • LDTs & Assay Services
  • Simoa p-Tau 217
  • Simoa NfL LDT
  • Simoa p-Tau 181 LDT
  • HD-X Automated Immunoassay Analyzer
  • SR-X Biomarker Detection System
  • SP-X Imaging and Analysis System
  • Simoa Accelerator Laboratory
  • Homebrew - Custom Assay Development
  • Uman NF-Light

The Simoa bead-based and planar array platforms are designed to detect protein biomarkers in low concentrations in blood, serum, and other fluids, which are undetectable using conventional analog immunoassay technologies.

Quanterix continues to push the boundaries of precision health for life sciences research and diagnostics, tackling significant unmet needs and contributing meaningfully to the scientific community.

News

Quanterix To Participate at The Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

Rhea-AI Summary
Quanterix Corporation (NASDAQ: QTRX) Announces CEO's Participation in Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum. President and CEO Masoud Toloue will speak in a fireside chat on November 16, 2023, at 3:00 PM ET. The live webcast can be accessed by registering on the company's website, with a replay available afterward. This event aims to provide insights into the company's strategic direction and industry trends.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.47%
Tags
conferences
-
News

Quanterix Releases Operating Results for Third Quarter 202

Rhea-AI Summary
Quanterix Corporation (NASDAQ: QTRX) reported its financial results for the third quarter of 2023. The company's revenue increased by 18% to $31.3 million compared to the same period last year. GAAP gross margin improved to 56.8% from 41.1% in the prior year period. Net loss for the quarter was $7.8 million, a significant decrease from $35.1 million in the corresponding prior year period. Quanterix also announced the launch of LucentAD p-Tau 217, a blood-based biomarker laboratory developed test for Alzheimer's disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.18%
Tags
earnings
-
News

Quanterix to Report Third Quarter 2023 Financial Results on November 7, 2023

Rhea-AI Summary
Quanterix Corporation (NASDAQ: QTRX) will report financial results for Q3 2023 on November 6, 2023. A webcast and conference call will be held on November 7, 2023 at 8:30 a.m. E.T. Interested investors can pre-register for the conference call and access the live webcast from the Quanterix website. An archived webcast replay will be available on the website for one year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.59%
Tags
conferences earnings
News

Quanterix Launches High Accuracy p-Tau 217 Blood Biomarker Test to Aid Physician Diagnosis of Alzheimer’s Disease

Rhea-AI Summary
Lucent Diagnostics, a diagnostics brand of Quanterix Corporation, has announced the expansion of its LucentAD product line with the addition of a high accuracy p-Tau 217 blood test for Alzheimer’s disease. The test marks a major advance in the performance of blood biomarker tests for assessing amyloid pathology in individuals with memory complaints. The LucentAD p-Tau 217 test achieved an overall accuracy exceeding 90%, meeting the requirements set forth in the most recent NIA-AA Revised Criteria for Diagnosis and Staging of Alzheimer's Disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.83%
Tags
none
-
News

Quanterix Announces New Agreement to Advance Blood Based Alzheimer's Disease Detection

Rhea-AI Summary
Quanterix signs license agreement with Janssen to access p-Tau 217 antibodies for Alzheimer's Disease research and diagnostics. Quanterix will have worldwide rights to produce assay kits and launch a Laboratory Developed Test based on the antibodies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.36%
Tags
none
-
News

Quanterix CEO to Speak at Goldman Sachs Alzheimer’s Disease Day

Rhea-AI Summary
Quanterix CEO to speak at Goldman Sachs Alzheimer’s Disease Day on October 3, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.93%
Tags
conferences
News

Quanterix to Participate at the Morgan Stanley 21st Annual Global Healthcare Conference

Rhea-AI Summary
Quanterix CEO to participate in fireside chat at Morgan Stanley conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.86%
Tags
conferences
-
News

William P. Donnelly Appointed to Quanterix’s Board of Directors

Rhea-AI Summary
Quanterix Corporation appoints William P. Donnelly to its Board of Directors
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.15%
Tags
management
-
News

Quanterix Appoints Vandana Sriram as Chief Financial Officer

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.81%
Tags
management
News

Quanterix Releases Operating Results for Second Quarter 2023

Rhea-AI Summary
Quanterix Corporation reports Q2 2023 financial results, with total revenue of $31.0 million, a 32% increase YoY. GAAP gross margin improved to 61.7% from 37.1% in Q2 2022. Net loss was $6.1 million, an improvement from $24.9 million in Q2 2022. Cash and cash equivalents remained stable at $329.5 million. Quanterix expects full-year revenue to be in the range of $110 to $116 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.89%
Tags
earnings

FAQ

What is the current stock price of Quanterix Corporation (QTRX)?

The current stock price of Quanterix Corporation (QTRX) is $10.21 as of January 23, 2025.

What is the market cap of Quanterix Corporation (QTRX)?

The market cap of Quanterix Corporation (QTRX) is approximately 483.3M.

What is the core technology of Quanterix Corporation?

The core technology of Quanterix Corporation is Single Molecule Array (Simoa™) technology, which enables ultra-sensitive detection and quantification of protein biomarkers.

What are some applications of Quanterix's technology?

Quanterix's technology is used in life sciences research, in-vitro diagnostics, companion diagnostics, and blood screening.

Who founded Quanterix Corporation?

Quanterix Corporation was founded by Dr. David Walt, who also co-founded Illumina.

What product platforms does Quanterix offer?

Quanterix offers the Simoa platform, Assay Kits, LDTs & Assay Services, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, and more.

What makes Quanterix's diagnostic platform unique?

Quanterix's diagnostic platform is unique for its ability to measure individual proteins at concentrations 1000 times lower than conventional immunoassays.

Is Quanterix publicly traded?

Yes, Quanterix Corporation is publicly traded on NASDAQ under the symbol QTRX.

What significant achievements has Quanterix made recently?

Quanterix has significantly advanced precision health by developing platforms that allow for ultra-sensitive detection of biomarkers.

What fluids can Quanterix's platforms detect biomarkers in?

Quanterix's platforms can detect biomarkers in blood, serum, and other fluids.

Does Quanterix offer custom assay development?

Yes, Quanterix offers Homebrew - Custom Assay Development services.

What is the Simoa Accelerator Laboratory?

The Simoa Accelerator Laboratory is a facility provided by Quanterix for advanced biomarker detection and research.
Stock QTRX logo
Quanterix Corporation

Nasdaq:QTRX

QTRX Rankings

#3143 Ranked by Market Cap
N/A Ranked by Dividends

QTRX Stock Data

483.33M
44.00M
6.54%
88.53%
5.17%
Medical Devices
Laboratory Analytical Instruments
Link
United States of America
BILLERICA